Full Text
Secukinumab Vs Adalimumab for the Treatment of Psoriasic Arthritis- a Cost Per Responder Analysis at 48 Weeks from a Peruvian Perspective for Public and Private Health Schemes

Abstract

Authors

A Patino E Karpf

Back to Volume 20, Issue 9
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×